Trials / Recruiting
RecruitingNCT06586593
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)
ETUDE NEOMEL: TRAITEMENT NEOADJUVANT PAR IMMUNOTHERAPIE DU MELANOME METASTATIQUE OPERABLE EN VIE REELLE (GCC)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 77 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma. The complete histological response will be assessed.
Conditions
Timeline
- Start date
- 2023-03-24
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
- First posted
- 2024-09-19
- Last updated
- 2024-09-19
Locations
9 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06586593. Inclusion in this directory is not an endorsement.